From: Hereditary cancer risk assessment: essential tools for a better approach
Syndrome | Model | Genes included* | Clinical criteria/tumors included* |
---|---|---|---|
Hereditary breast and ovarian cancer | Couch, Penn II, Myriad, Tyrer-Cuzick, BRCAPRO, BOADICEA | BRCA1 | Breast cancer (age<45, two primaries, male) |
BRCA2 | |||
Ovarian cancer | |||
Pancreatic cancer | |||
Prostate cancer | |||
Ashkenazi ancestry | |||
Family history (one side) | |||
Lynch | Wijnen, MMRpro, MMRPredict, PREMM1,2,6 | MLH1 | Amsterdam I and II |
MSH2 | Bethesda (revised) | ||
MSH6 | Colorectal cancer | ||
Endometrial cancer | |||
Li-Fraumeni and Li-Fraumeni like | none | none | Classic |
Eeles | |||
Chompret (revised) | |||
Cowden | Cleveland clinic | PTEN | International Cowden Consortium |
Thyroid, oral papillomas, acral keratoses, skin lipomas, trichilemmomas, uterine leiomyomas, gastrointestinal polyps, dysplastic cerebellar gangliocytoma, fibrocystic breast disease | |||
Hereditary melanoma | MELApro | CDKN2A | Melanoma |